Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Exatecan derivative for ADC (DXD) is an inhibitor targeting DNA topoisomerase I, belonging to the camptothecin (CPT) class of compounds. DNA topoisomerase I inhibitors currently stand as the most promising ADC payloads, causing DNA damage and cell apoptosis by cleaving single-strand DNA and suppressing the topoisomerase repair mechanism. The new generation DXD-ADC employs DXD as a drug carrier (payload) that effectively determines DXD stability and release efficiency, applicable in plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug binding affinity, analysis of Drug Antibody Ratio (DAR), and evaluation of ADC drug efficacy.
Figure. 1 DXD-the most promising payload for next-generation ADCs [1]
This tool serves as a core instrument for conducting PK (Pharmacokinetic) analysis of DXD-ADCs and qualitative analysis of coupled DAR values, expediting the R&D process of ADC drugs.
High Purity
Purity validated to be over 90% through SDS-PAGE.
High Sensitivity
Anti-DXD antibody activity verified through binding with leading ADC drug DS-8201.
Expert Technical Team
Responsive within 24 hours for any pre-sales or after-sales inquiries.
| Code | Product Name | Application |
|---|---|---|
| CSB-MA996977I1m | DXD Monoclonal Antibody | ELISA |
| CSB-MA996977I1m-B | DXD Monoclonal Antibody, HRP conjugated | ELISA |
| CSB-MA996977I2m | DXD Monoclonal Antibody | ELISA |
| CSB-MA996977I2m-B | DXD Monoclonal Antibody, HRP conjugated | ELISA |
More: Anti-Payload Antibody DXD: a Highly Potent Tool for ADCs Pharmacokinetic (PK) Analysis!
References
[1] https://xueqiu.com/8965749698/192610616
